Compare Eni SpA (E) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Inovio Pharmaceuticals Inc — how do they compare? Eni SpA trades at $56 (market cap $79.81B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Eni SpA is far larger — about 711.4× Inovio Pharmaceuticals Inc's market cap, and Eni SpA pays a 4.39% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| E | INO | |
|---|---|---|
Market Cap | $79.81B | $112.19M |
Volume | 365,912 | 3,201,278 |
Sector | Energy | Health |
52-Week High | $57.61 | $2.60 |
52-Week Low | $34.03 | $0.66 |
Typical Hold Time | 53 Days | 43 Days |
Enterprise Value | $104.34B | $83.51M |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $55.62, up 3.08% today, showing strong momentum with bullish technical signals from moving averages. The stock appears undervalued with a P/E of 12.87 and P/S of 0.85, while recent earnings show mixed results with two misses but a Q4 2025 beat. Revenue has declined from $132.5B in 2022 to $82.2B in 2025, though net income margin improved to 5.97% in 2026 projections. Recent developments include expansion in Venezuela oil opportunities and humanoid robotics partnerships.
The outlook remains cautiously optimistic given the attractive valuation and dividend yield, but investors face risks from volatile energy prices and inconsistent earnings performance. Analyst consensus leans neutral with 62% hold ratings, reflecting concerns about revenue trends despite solid cash flow generation. The stock's current technical strength suggests near-term upside potential if fundamental improvements materialize.
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
